Table 2.

Characteristics of Patients Who Newly Engaged in PTSD Treatment in the VA Healthcare System, Carried a Comorbid Diagnosis of Opioid Use Disorder and Received MAT

	% (n)
Total population	100.0 (5,901)
Baseline characteristics
Male^a	93.4 (5,507)
Age, Mean (SD)	43.3 (13.8)
Demographics^a
Black	22.9 (1,339)
Hispanic	6.1 (361)
Marital status
Married	26.0 (1536)
Divorced/separated	43.3 (2554)
Other (never/widow/unknown)	30.7 (1811)
Psychiatric comorbidities^b
Anxiety Disorders	69.0 (4,072)
Mood Disorders	50.8 (3,000)
Alcohol Dependence/Abuse	38.7 (2,285)
Medical comorbidities^c
Hepatitis	22.9 (1,349)
Diabetes	10.5 (2,093)
COPD	5.9 (351)
Cancer	0.7 (133)
Treatment in the first year following index date
MAT^d Buprenorphine	48.0 (2,833)
Methadone	55.9 (3,299)
Naltrexone	16.8 (994)
Days of MAT
1–7 days	9.4 (555)
8–30 days	14.6 (863)
31–100 days	19.0 (1,120)
>100 days	57.0 (3,363)
Days of general substance abuse treatment visits
None	9.5 (563)
1–7 days	17.6 (1,036)
8–30 days	32.6 (1,924)
31–100 days	36.0 (2,127)
>100 days	4.3 (251)
Days of general substance abuse treatment & methadone maintenance visits
None	3.1 (181)
1–7	7.9 (464)
8–30	22.6 (1,332)
31–100	34.7 (2,046)
>100 days	31.8 (1,878)
Overall one-year crude mortality rate	1.4 (81)
One-year crude mortality rate due to external cause	0.8 (50)
One-year crude mortality rate due to overdose or suicide	0.5 (31)

Note. MAT: medication-assisted therapy; PSTD: posttraumatic stress disorder; COPD: chronic obstructive pulmonary disease.

There was <1% missing data for each demographic characteristic.

Results shown for psychiatric comorbidities that are commonly observed in patients with PTSD (Brady, Killeen, Brewerton, & Lucerini, 2000).

Results shown for medical comorbidities that have been shown to be common causes of death in patients with PTSD (Forehand et al., 2019).

While patients could have been trialed on several different types of MAT during the follow-up period, it was uncommon that a patient was on more than one type of MAT at any given time.